Area of research
Dermatology · Pathology and Forensic Medicine
Research interest
Research interests include Cutaneous lymphoproliferative disorders research, Lymphoma Diagnosis and Treatment, Nail Diseases and Treatments, and CNS Lymphoma Diagnosis and Treatment.
Prognosis of increasing percentages of lesional body surface area in early stage mycosis fungoides.
European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders
Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG "PARCT".
Detection of Circulating Tumor DNA for Disease Monitoring in Patients with Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders.
Histopathologic Evaluation of Density and Depth of the Lymphoid Infiltrate in Clinically Defined Patches and Plaques in Early Stage Mycosis Fungoides.
Added value of pathology consultations in cutaneous lymphomas: a 2-year review from the Dutch national referral and expertise centre.
Classifications of cutaneous lymphomas and lymphoproliferative disorders: An update from the EORTC cutaneous lymphoma histopathology group.
Cutaneous lymphoproliferative disorders: Back to the future.
Evaluation of Quality of Life and Treatment Satisfaction in Newly Diagnosed Cutaneous T-Cell Lymphoma Patients.
Primary cutaneous acral CD8+ T-cell lymphoproliferative disorder: a benign or malignant process?
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.
Clinical, histopathological and prognostic features of primary cutaneous acral <scp>CD8</scp> <sup>+</sup> T‐cell lymphoma and other dermal <scp>CD8</scp> <sup>+</sup> cutaneous lymphoproliferations: results of an <scp>EORTC</scp> Cutaneous Lymphoma Group workshop*
Primary cutaneous lymphoma: the 2018 update of the WHO-EORTC classification.
Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider.
Tumor Clone Frequency Calculation Using High-Throughput Sequencing of the TCRβ Gene in Patients with Folliculotropic Mycosis Fungoides.
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Incidence of mycosis fungoides and Sézary syndrome in the Netherlands between 2000 and 2020.
Treatment of early‐stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*
The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas
Acquired N-Linked Glycosylation Motifs in B-Cell Receptors of Primary Cutaneous B-Cell Lymphoma and the Normal B-Cell Repertoire.
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium
Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients
Genome‐wide promoter methylation analysis identifies epigenetic silencing of <scp><i>MAPK</i></scp><i>13</i> in primary cutaneous melanoma
No Acceleration of UV-Induced Skin Carcinogenesis from Evenly Spread Dietary Intake of Cyclosporine in Contrast to Oral Bolus Dosages
Dietary Immunosuppressants Do Not Enhance UV-Induced Skin Carcinogenesis, and Reveal Discordance between p53-Mutant Early Clones and Carcinomas